
A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease
Keywords: بقا بدون پیشرفت; ILD; interstitial lung disease; IPF; idiopathic pulmonary fibrosis; AE; acute exacerbation; AE-ILD; acute exacerbation of interstitial lung disease; NSCLC; non-small cell lung cancer; S-1; tegafur-gimeracil-oteracil potassium; CBDCA; carboplatin; RECIST;